/C O R R E C T I O N -- Eli Lilly and Company/

ConferenceP-tau217 blood testAmyloid-targeting treatmentNeutral

AI Analysis

Summary

Eli Lilly issued a correction notice regarding a previously announced presentation of Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment.

Importance:2/10

Sentiment:

0.00

Alzheimer's diseasediagnosticbiomarkerAAIC 2026correction notice

Related Companies

$LLY

Read the original article

Published by PR Newswire Clinical Trials on July 9, 2026 5:16 PM

Read Original